Evidence map›Paper›PMID 37614373›Full record

ArticleMolecular and clinical oncology2023

Comparison of the outcomes following bevacizumab and/or temozolamide/radiosurgery treatment in patients with glioblastoma.

Aikaterini Aravantinou-Fatorou, Vasiliki Epameinondas Georgakopoulou, Nikolaos Mathioudakis, Petros Papalexis, Kyriakos Tarantinos, Ilias Trakas, Nikolaos Trakas, Demetrios A Spandidos, George Fotakopoulos

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Aikaterini Aravantinou-FatorouFirst Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Vasiliki Epameinondas GeorgakopoulouDepartment of Infectious Diseases and COVID-19 Unit, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Nikolaos MathioudakisDepartment of Renal Transplantation, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Petros PapalexisUnit of Endocrinology, First Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Kyriakos TarantinosFirst Pulmonology Department, Sismanogleio Hospital, Athens 15126, Greece.
Ilias TrakasFirst Department of Internal Medicine, Laiko General Hospital, Medical School, National and Kapodistrian University of Athens, Athens 11527, Greece.
Nikolaos TrakasDepartment of Biochemistry, Sismanogleio Hospital, Athens 15126, Greece.
Demetrios A SpandidosLaboratory of Clinical Virology, School of Medicine, University of Crete, Heraklion 71003, Greece.
George FotakopoulosDepartment of Neurosurgery, General University Hospital of Larisa, Larisa 41221, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma multiforme (GBM) is the most frequent and malignant primary central nervous system tumor in adults. The gold-standard management of GBM includes post-operative radiotherapy (RT) with concurrent and secondary temozolomide (TMZ) treatment. The present meta-analysis study examined the efficacy of the early administration of bevacizumab prior to standard RT plus TMZ in managing patients with GBM and unfavorable prognostic factors. Between 1983 and 2020, the present study looked for comparative articles involving standard RT plus TMZ and RT/TMZ combined with bevacizumab treatment in patients with GBM. The primary outcomes involved in this study include progression-free survival and overall survival. The present study suggested that bevacizumab administration plus standard RT/TMZ (BEV group) treatment was associated with increased survival of patients with GBM compared with those treated with standard RT/TMZ (CG/Control group) treatment only.

Indexed as

bevacizumabchemoradiotherapychemotherapyradiotherapytemozolomide

Identifiers

PMID37614373
PMCPMC10442729

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.